Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | CES1 | P23141 | 4/20 | 0.50 |
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28960147 | 0.80 | TDP1 (0.56) | TDP1L3MBTL1CES1CES2LMNA | |
| SCHEMBL8445181 | 0.80 | CES1 (0.60) | TDP1L3MBTL1CES1CES2LMNA | |
| SCHEMBL2417683 | 0.80 | TDP1 (0.56) | TDP1L3MBTL1CES1CES2LMNA | |
| SCHEMBL4380823 | 0.78 | CES1 (0.58) | TDP1L3MBTL1CES1CES2LMNA | |
| SCHEMBL1167722 | 0.76 | L3MBTL1 (0.52) | TDP1L3MBTL1CES1CES2LMNA | |
| SCHEMBL11377658 | 0.76 | TDP1 (0.52) | TDP1L3MBTL1CES1CES2LMNA | |
| SCHEMBL9211939 | 0.76 | TDP1 (0.52) | TDP1L3MBTL1CES1CES2LMNA | |
| SCHEMBL7207824 | 0.76 | TDP1 (0.52) | TDP1L3MBTL1CES1CES2LMNA | |
| SCHEMBL932126 | 0.76 | TDP1 (0.52) | TDP1L3MBTL1CES1CES2LMNA | |
| SCHEMBL5274104 | 0.76 | TDP1 (0.52) | TDP1L3MBTL1CES1CES2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311960-A1 | Phosphinoamidite Carboxylates and Analogs Thereof in the Synthesis of Oligonucleotide Having Reduced Internucleotide Charge | LIEVRE CORNU LLC (US) | 2010-12-09 | — | — | US | claimed |
| US-7745591-B2 | phosphinocarboxylate and phosphonocarboxylate oligonucleotides having enhanced nuclease resistance | Lievre Cornu, LLC (US) | 2010-06-29 | — | — | US | claimed |
| US-7427679-B2 | Precursors for two-step polynucleotide synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2008-09-23 | — | — | US | claimed |
| US-7417139-B2 | Method for polynucleotide synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2008-08-26 | — | — | US | claimed |
| US-7385050-B2 | Cleavable linker for polynucleotide synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2008-06-10 | — | — | US | claimed |
| US-7193077-B2 | Exocyclic amine triaryl methyl protecting groups in two-step polynucleotide synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2007-03-20 | — | — | US | claimed |
| EP-1334111-A4 | PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE | DELLINGER DOUGLAS J (US) | 2007-01-24 | — | — | EP | claimed |
| US-20060293511-A1 | phosphinocarboxylate and phosphonocarboxylate oligonucleotides having enhanced nuclease resistance | LIEVRE CORNU LLC (US) | 2006-12-28 | — | — | US | claimed |
| US-7067641-B2 | Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge | LIEVRE CORNU LLC (US) | 2006-06-27 | — | — | US | claimed |
| US-20050048497-A1 | Cleavable linker for polynucleotide synthesis | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2005-03-03 | — | — | US | claimed |
| US-20050048601-A1 | Method for polynucleotide synthesis | REGENTS OF THE UNIVERSITY OF COLORADO, THE | 2005-03-03 | — | — | US | claimed |
| EP-1510523-A1 | Precurors for two-step polynucleotide synthesis | Agilent Technologies Inc (US) | 2005-03-02 | — | — | EP | claimed |
| EP-1334111-A2 | PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE | Dellinger, Douglas J. (US) | 2003-08-13 | — | — | EP | claimed |
| WO-2002032912-A2 | PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE | DELLINGER DOUGLAS J (US) | 2002-04-25 | — | — | WO | claimed |
| WO-2024006953-A2 | MONOMERS AND METHODS FOR SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| CN-110461858-A | Acyl nucleosides phosphonate ester, its prodrug and its purposes as drug | UNIV MONTPELLIER | 2019-11-15 | — | — | CN | disclosed |
| US-8097711-B2 | nucleoside monomers protected with thioether substituted aryl carbonate protecting groups; oligonucleotides, using such protected nucleoside monomer monomers, as well as nucleic acids | AGILENT TECHNOLOGIES, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| WO-2002032912-A2 | PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE | DELLINGER DOUGLAS J (US) | 2002-04-25 | — | — | WO | disclosed |
| EP-1051419-A1 | DEPROTECTION AND RECRYSTALLIZATION PROCESSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999035145-A1 | DEPROTECTION AND RECRYSTALLIZATION PROCESSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050048601-A1 | Method for polynucleotide synthesis | POLN, RNGTT, NSUN2 | TDP1 155/4885L3MBTL1 905/4885CES1 3226/4885 |
| US-20100311960-A1 | Phosphinoamidite Carboxylates and Analogs Thereof in the Synthesis of Oligonucleotide Having Reduced Internucleotide Charge | NSUN2, POLL, DUT | TDP1 485/4885L3MBTL1 46/4885CES1 3049/4885 |
| US-20050048497-A1 | Cleavable linker for polynucleotide synthesis | TYMP, POLN, CPSF1 | TDP1 53/4885L3MBTL1 2004/4885CES1 2420/4885 |
| US-20060293511-A1 | phosphinocarboxylate and phosphonocarboxylate oligonucleotides having enhanced nuclease resistance | NSUN2, ADAR, POLL | TDP1 199/4885L3MBTL1 42/4885CES1 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.